View Older Stories View More Recent Stories

May 10, 2022 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
May 4, 2022 04:15PM NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
May 2, 2022 04:15PM New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
Apr 11, 2022 04:16PM Nanobiotix S.A. (NBTX) Reports New Preclinical Immunotherapy Data Showing Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated N
Apr 11, 2022 04:15PM NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
Apr 8, 2022 05:57PM NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
Apr 7, 2022 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Mar 30, 2022 04:22PM NANOBIOTIX (NANO) Provides Business Update, Report FY21 Results
Mar 30, 2022 04:21PM  NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
Mar 16, 2022 04:15PM NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
Mar 8, 2022 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Feb 10, 2022 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Feb 9, 2022 04:15PM Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Jan 26, 2022 04:15PM NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
Jan 11, 2022 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Jan 10, 2022 05:34AM Nanometrics, Inc. (NANO) Issues Corporate Update, Outlines Key 2022 Milestones
Jan 10, 2022 02:00AM NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Jan 5, 2022 04:15PM NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
Jan 4, 2022 04:15PM Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
Dec 8, 2021 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Nov 17, 2021 04:15PM NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 9, 2021 04:15PM NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
Nov 8, 2021 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Nov 3, 2021 04:15PM NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
Oct 25, 2021 05:29AM Nanobiotix (NBTX) Reports 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
Oct 24, 2021 05:02PM NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
Oct 20, 2021 04:15PM NANOBIOTIX Provides Third Quarter Operational and Financial Update
Oct 8, 2021 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Oct 6, 2021 04:15PM NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
Sep 28, 2021 04:18PM Nanometrics, Inc. (NANO) Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscop
Sep 28, 2021 04:15PM NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
Sep 9, 2021 04:15PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
Sep 8, 2021 04:15PM NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
Sep 7, 2021 04:15PM Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 6, 2021 12:00PM Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of July 31, 2021
Jul 20, 2021 04:15PM Nanobiotix Provides Second Quarter Operational and Financial Update
Jun 30, 2021 04:15PM NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
Jun 7, 2021 04:15PM NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
Jun 3, 2021 04:50PM NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior
Jun 1, 2021 04:17PM Nanobiotix S.A. (NBTX) Appoints Bart Van Rhijn as its CFO and Executive Board Member
Jun 1, 2021 04:15PM NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
May 26, 2021 04:15PM NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
May 25, 2021 04:32PM Nanobiotix S.A. (NBTX) Adds Gary Phillips, MD as Board Chair, Succeeding Laurent Condomine
May 25, 2021 04:15PM Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
May 21, 2021 06:35PM CORRECTING and REPLACING: Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting
May 21, 2021 06:34PM CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting
May 19, 2021 05:19PM Nanobiotix (NBTX) Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3
May 19, 2021 05:18PM Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society f
May 12, 2021 04:15PM Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
May 11, 2021 04:15PM NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
View More Recent Stories View Older Stories